Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
194.67
+1.07 (+0.55%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
47
48
Next >
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Recap: Biogen Q1 Earnings
May 03, 2022
Biogen (NASDAQ:BIIB) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder
May 02, 2022
Via
Benzinga
Earnings Preview For Biogen
May 02, 2022
Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Biogen will report an...
Via
Benzinga
Biogen Fails To Convince Benefits Of Alzheimer's Drug To European Regulator
April 22, 2022
Via
Benzinga
Why Biogen Stock Looks 'Too Good To Ignore,' According To One Analyst
April 18, 2022
Biogen stock could see a resurgence later this year, according to one analyst.
Via
Investor's Business Daily
Bear Of The Day: Biogen
April 04, 2022
Biogen’s MS revenues were $1.79 billion in the reporter quarter, including Ocrevus royalties, which declined 1% (both actual and constant currency basis) year over year.
Via
Talk Markets
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)
May 02, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
3 Undervalued Stocks to Buy This Week
March 30, 2022
Here are the three undervalued stocks to buy this week.
Via
Talk Markets
If You Invested $100 In Biogen 15 Years Ago, Here's How Much You Would Have Today
April 22, 2022
Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.88% on an annualized basis producing an average annual return of 11.31%. Currently, Biogen has a market capitalization of...
Via
Benzinga
Analyst Ratings for Biogen
April 21, 2022
Over the past 3 months, 15 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
Biogen Earnings Conference Call Is Coming Up, Here's What You Need To Know
April 21, 2022
Biogen (NASDAQ:BIIB) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
April 21, 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.
Via
InvestorPlace
Why This Analyst Believes Biogen Is 'Too Good to Ignore'
April 18, 2022
Biogen Inc’s (NASDAQ: BIIB) base business seems to be worth more than what the Street estimates, and it is possible that investors are not properly valuing royalty streams coming to the company, which...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022
April 18, 2022
Upgrades
Via
Benzinga
Biogen’s Aduhelm Crashes the Biotech Sector
April 13, 2022
Aduhelm's quick approval and high price have set off pushback on the whole FDA and Medicare drug process which is not good for BIIB stock.
Via
InvestorPlace
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
April 08, 2022
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now.
Via
InvestorPlace
Friday Stocks Update
April 08, 2022
Royal Dutch Shell rose again on its earnings but is still at a p/e ratio of under 11x earnings.
Via
Talk Markets
How Medicare 'Snuffed Out' Hope For Biogen's Controversial Alzheimer's Drug
April 08, 2022
Only Medicare patients enrolled in specific studies will receive reimbursement.
Via
Investor's Business Daily
Why Is Trevi Therapeutics (TRVI) Stock On the Move Today?
April 08, 2022
Trevi Therapeutics (TRVI) stock is slipping on Friday but that's only after the biopharmaceutical company saw a massive rally yesterday.
Via
InvestorPlace
Why Is Biogen (BIIB) Stock in the Spotlight Today?
April 08, 2022
Medicare's decision not to cover the cost of the drug maker's expensive Alzheimer's drug is hitting the company's stock price today.
Via
InvestorPlace
Morning Brief: Top Stories Dominating Financial Media on Friday, April 8
April 08, 2022
Reuters Blockchain-Based Online Games Like Axie Infinity Continue To Hook Users Despite Risks Blockchain-based online games like Axie Infinity, dubbed “play-to-earn,...
Via
Benzinga
Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks
April 08, 2022
Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies.
Via
InvestorPlace
Biogen's Alzheimer's Drug Aduhelm Medicare Coverage Restricted To Just Clinical Trials, CMS Finalizes
April 08, 2022
Centers for Medicare and Medicaid Services (CMS) finalized its decision to restrict coverage for Biogen Inc's (NASDAQ:&
Via
Benzinga
Keep Eyes on Momentum in the Small-Cap Index and The Biotech Space
April 06, 2022
If BIIB can clear and close over roughly $212, it would confirm that price and momentum agree and show it's potentially ready for another move higher.
Via
Talk Markets
Amylyx Pharmaceuticals Stock Crashes As FDA Doubts Its ALS Treatment
March 28, 2022
Amylyx Pharmaceuticals could face an uphill battle for its ALS treatment this week.
Via
Investor's Business Daily
Biogen Inc. (NASDAQ:BIIB) Investor Notice: Deadline in Lawsuit on April 8, 2022
March 28, 2022
San Diego, CA -- (SBWIRE) -- 03/28/2022 -- The Shareholders Foundation announced that a deadline is coming up on April 8, 2022 in the lawsuit filed for certain investors of Biogen Inc. (NASDAQ:BIIB).
Via
SBWire
Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints
March 28, 2022
Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have
Via
Benzinga
Why I Sold Kohl’s Corporation Despite Possible Buyout Deal
March 22, 2022
2022 has been a headline-packed for Kohl’s and KSS stock. But after a closer look at my portfolio grader, this is why it was time to sell.
Via
InvestorPlace
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
47
48
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.